Efficacy and safety of fexuprazan versus esomeprazole for healing of endoscopic submucosal dissection-induced artificial gastric ulcers: A multicenter, randomized, open-label, active-controlled trial

BACKGROUND: Endoscopic submucosal dissection (ESD) is a standard treatment for gastric neoplasms but creates artificial ulcers requiring potent acid suppression. Potassium-competitive acid blockers (P-CABs) provide rapid and sustained acid suppression. This study compared the efficacy and safety of fexuprazan, a novel P-CAB, with esomeprazole for the healing of artificial gastric ulcers after ESD. METHODS: This multicenter, randomized, open-label, active-controlled trial enrolled patients who underwent gastric ESD. Patients were randomly assigned (1:1) to receive either fexuprazan 40 mg or esomeprazole 40 mg once daily for 8 weeks. The primary endpoint was the ulcer healing rate at 8 weeks. Secondary endpoints included the incidence of delayed bleeding and adverse events. RESULTS: Of 105 randomized patients, 90 were included in the full analysis set (FAS) and 85 in the per-protocol set (PPS). At 8 weeks, the complete healing rate (scar stage) in the PPS was 92.68% (38/41) in the fexuprazan group and 95.45% (42/44) in the esomeprazole group (95% confidence interval: 80.08-98.46 vs 84.53-99.44, P = .67), with an absolute difference of -2.77 percentage points (95% confidence interval: -15.32-8.85). Results were consistent in the FAS (93.02% vs 95.74%, 95% confidence interval: 80.94-98.54 vs 85.46-99.48, P = .67), with an absolute difference of -2.72 percentage points (95% confidence interval: -14.75-8.27). At 8 weeks, no patients in either group remained in the active stage. No delayed bleeding occurred in either group. Treatment-emergent adverse events were minimal and similar between groups (2.00% vs 4.08%, P > .62), with no serious adverse events. CONCLUSION: Fexuprazan 40 mg once daily showed no statistically significant difference from esomeprazole 40 mg for healing ESD-induced artificial gastric ulcers, with a favorable safety profile. These findings indicate that fexuprazan serves as a reasonable candidate for further investigation as a potential treatment option to proton pump inhibitors for post-ESD ulcer healing.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-13
DOI
https://doi.org/10.1097/md.0000000000051530
Primary Topic
Gastroesophageal reflux and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and safety of fexuprazan versus esomeprazole for healing of endoscopic submucosal dissection-induced artificial gastric ulcers: A multicenter, randomized, open-label, active-controlled trial

Seung Young Seo, Geom Seog Seo, Jin Woong Cho
1 links
Medicine
Gastroesophageal reflux and treatments
article

Efficacy and safety of fexuprazan versus esomeprazole for healing of endoscopic submucosal dissection-induced artificial gastric ulcers: A multicenter, randomized, open-label, active-controlled trial

Seung Young Seo, Geom Seog Seo, Jin Woong Cho
article en

Abstract

BACKGROUND: Endoscopic submucosal dissection (ESD) is a standard treatment for gastric neoplasms but creates artificial ulcers requiring potent acid suppression. Potassium-competitive acid blockers (P-CABs) provide rapid and sustained acid suppression. This study compared the efficacy and safety of fexuprazan, a novel P-CAB, with esomeprazole for the healing of artificial gastric ulcers after ESD. METHODS: This multicenter, randomized, open-label, active-controlled trial enrolled patients who underwent gastric ESD. Patients were randomly assigned (1:1) to receive either fexuprazan 40 mg or esomeprazole 40 mg once daily for 8 weeks. The primary endpoint was the ulcer healing rate at 8 weeks. Secondary endpoints included the incidence of delayed bleeding and adverse events. RESULTS: Of 105 randomized patients, 90 were included in the full analysis set (FAS) and 85 in the per-protocol set (PPS). At 8 weeks, the complete healing rate (scar stage) in the PPS was 92.68% (38/41) in the fexuprazan group and 95.45% (42/44) in the esomeprazole group (95% confidence interval: 80.08-98.46 vs 84.53-99.44, P = .67), with an absolute difference of -2.77 percentage points (95% confidence interval: -15.32-8.85). Results were consistent in the FAS (93.02% vs 95.74%, 95% confidence interval: 80.94-98.54 vs 85.46-99.48, P = .67), with an absolute difference of -2.72 percentage points (95% confidence interval: -14.75-8.27). At 8 weeks, no patients in either group remained in the active stage. No delayed bleeding occurred in either group. Treatment-emergent adverse events were minimal and similar between groups (2.00% vs 4.08%, P > .62), with no serious adverse events. CONCLUSION: Fexuprazan 40 mg once daily showed no statistically significant difference from esomeprazole 40 mg for healing ESD-induced artificial gastric ulcers, with a favorable safety profile. These findings indicate that fexuprazan serves as a reasonable candidate for further investigation as a potential treatment option to proton pump inhibitors for post-ESD ulcer healing.

MedicineVol. 105(46)
Presbyterian Medical Center (KR), Jeonbuk National University Hospital (KR), Wonkwang University (KR), Jeonbuk National University (KR)
Good health and well-being
Gastroesophageal reflux and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon